Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAIS Ragweed placebo-controlled phase 3 study in ragweed allergic rhinoconjunctivitis
2014-004431-38Phase 3Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Jan 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing LAIS Ragweed with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2015; status: completed.
02
Drugs
LAIS Ragweed
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2014-004431-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004431-38.